Ads
related to: alpha-1 antitrypsin deficiency (aatd)
Search results
Vertex Moves Its Alpha-1 Antitrypsin Deficiency Program Forward
Benzinga via Yahoo Finance· 2 years agoVertex Pharmaceuticals Inc (NASDAQ: VRTX) has advanced its investigational program targeting alpha-1...
Sanofi to buy Inhibrx in deal worth up to $2.2B
BioPharma Dive via Yahoo Finance· 4 months agoThe acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new...
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 11 hours agoWave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript May 9, 2024 Wave Life Sciences...
Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder
Benzinga via Yahoo Finance· 2 years agoInhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an...
Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
Benzinga via Yahoo Finance· 2 years agoBased on discussions with the FDA, Inhibrx Inc (NASDAQ: INBX) has the potential to pursue...
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage
Benzinga via Yahoo Finance· 2 years agoBMO Capital Markets has raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $61 from...
Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?
Zacks via Yahoo Finance· 4 months agoIntellia Therapeutics, Inc. NTLA is a clinical-stage genome editing company focused on developing...
EastEnders' Sam Mitchell to make major New Year discovery
Digital Spy via Yahoo News· 4 months agoEastEnders spoilers follow. EastEnders' Sam Mitchell will make a major discovery in the New Year....
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced...
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
Motley Fool· 8 months agoOf course, it's complicated to figure out which are going to soar and which will languish, so it...